Trial Profile

Evaluating Inflammatory and Immunological Changes of HIV-positive Patients Switching to DTG Dual Regimen Compared to Those Switching to a Triple Drugs Regimen (B/F/TAF)

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 19 Dec 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bictegravir/emtricitabine/tenofovir alafenamide (Primary) ; Dolutegravir/lamivudine
Indications HIV-1 infections
Focus Therapeutic Use
Acronyms DEBATE

26 Oct 2022 Status changed to completed, as per results presented at the 16th International Congress on Drug Therapy and HIV Infection.
26 Oct 2022 Results assessing the immunological impact of switching to DTG/3TC or to bictegravir/emtricitabine/tenofovir alafenamide, presented at the 16th International Congress on Drug Therapy and HIV Infection.
05 Aug 2021 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verified Aug 2019).

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com